Picture a medicine that doesn’t rewrite your DNA, but quietly corrects a typo in the RNA message so the liver starts making the healthy version of a protective protein — and both lungs and liver get a better deal than today’s IV infusions. That’s the hopeful frame Wave Life Sciences is putting around WVE-006 after Oct. 1, 2026 feedback from the U.S. FDA on a registrational pathway for alpha-1 antitrypsin deficiency (AATD).
Wave says it is aligned with the FDA on key pieces: planning for a single two-year registrational trial that could support full approval, with a one-year interim analysis aimed at possible accelerated approval based on AATD biomarkers. The agency also supports Wave’s current LC-MS assay to measure wild-type M-AAT and mutant Z-AAT protein for the registrational program — a concrete lab detail that matters when biomarkers are the interim yardstick.
WVE-006 is a GalNAc-conjugated, subcutaneously delivered A-to-I RNA editing oligonucleotide (an “AIMer” in Wave’s toolkit). In people with the homozygous Pi\*ZZ mutation, a single RNA base fix is designed to restore healthy M-AAT, reduce unhealthy Z-AAT aggregates in the liver, and dynamically raise AAT that protects lungs — especially when levels crash during exacerbations. Wave’s CMO notes that today’s IV augmentation can leave patients depleted during lung flares and does not address liver disease risk; WVE-006 is positioned as a potential lung-plus-liver approach with infrequent subcutaneous dosing. Wave also stresses that RNA editing avoids irreversible bystander edits, indels, and other off-target edits associated with DNA base editing — a distinction worth keeping clear from DNA-editing programs in neighboring rare-disease headlines (including separate gene-therapy stories such as uniQure’s, which are a different modality and not this pathway).
RestorAATion-2, the ongoing Phase 1b/2a open-label trial in Pi\*ZZ AATD, continues. Wave says it is on track to share 600 mg monthly multidose cohort data in the fourth quarter of 2026, and that WVE-006 has been generally safe and well tolerated with no liver toxicities to date in that update. About 200,000 people in the U.S. and Europe are homozygous for the Z allele, per Wave’s release — the population the company is trying to reach with a more comprehensive standard of care.
Ink, not pencil: FDA feedback on trial design is a green light to plan, not an approval. Accelerated approval at one year would still hinge on biomarker persuasion and later confirmation inside the same two-year construct Wave describes. Multidose efficacy and safety details are still upcoming in Q4. Rare-disease registrational paths can shift; this is alignment Wave is willing to announce, not a stamped label.
For families watching the AATD space — and for operators tracking rare-disease pipelines — the practical question is whether an RNA edit that spares DNA can close the gaps IV augmentation leaves: liver risk, flare-time AAT dips, clinic-chair infusions — with a subcutaneous cadence patients can live with.
Why it matters
AATD is a rare inherited condition, but its lesson is broad: when a protein is missing or misshapen, people can face early lung disease and liver damage while standard care only patches one side. Medicines that edit RNA — temporary messages — aim to restore the healthy protein without permanently rewriting the genome. If that approach works and stays safe, it is a template for treating the instruction slip, not just topping up the tank — more durable health for patients who have waited on incomplete options.
What’s next
Watch the Q4 2026 RestorAATion-2 600 mg monthly multidose readout, then how Wave finalizes and opens the two-year registrational trial with its one-year biomarker interim. Assay acceptance for M-AAT/Z-AAT via LC-MS is already a quiet enabler. The loud milestones will be interim biomarker packages and, later, clinical outcomes that could support full approval without a separate confirmatory study — exactly the efficiency Wave highlighted after the FDA meeting.
Sources: - https://www.globenewswire.com/news-release/2026/10/01/3372774/0/en/wave-life-sciences-announces-fda-feedback-supports-registrational-pathway-for-wve-006-rna-editing-in-aatd.html - https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-fda-feedback-supports (IR mirror; Cloudflare gate blocked automated fetch — full text confirmed via GlobeNewswire release above)